Becker's Healthcare November 10, 2023
The FDA on Nov. 9 granted approval to Ixchiq, the first vaccine to protect against chikungunya virus.
The single-dose vaccine was developed by Valneva, a French biotech company. It had been on an accelerated approval track with the FDA.
Although most cases of the mosquito-borne illness in the U.S. are acquired through travel, locally acquired infections have occurred. In 2014, there were 12 cases of locally acquired chikungunya in the U.S., according to CDC data. A single locally acquired case was also reported in 2015, but not since.
The infection could become more common in the U.S. as environmental changes make territories in new regions more habitable for the tropical, disease carrying mosquitoes....
Today's Sponsors
Today's Sponsor